Benazepril - Misplaced Pages

(Redirected from Lotensin) Medication used to treat high blood pressure and heart failure

Pharmaceutical compound

Benazepril
Clinical data


Pronunciation	/bəˈnæzəprɪl/
Trade names	Lotensin, others
AHFS/Drugs.com	Monograph
MedlinePlus	a692011
License data	US DailyMed: Benazepril
Routes of administration	By mouth
ATC code	C09AA07 (WHO)
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	96.7%
Metabolism	Liver glucuronidation
Elimination half-life	10-11 hours
Excretion	Kidney and bile duct
Identifiers
IUPAC name 2-amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
CAS Number	86541-75-5
PubChem CID	5362124
IUPHAR/BPS	6374
DrugBank	DB00542
ChemSpider	4514935
UNII	UDM7Q7QWP8
KEGG	D07499 D00620
ChEBI	CHEBI:3011
ChEMBL	ChEMBL838
CompTox Dashboard (EPA)	DTXSID5022645
Chemical and physical data
Formula	C₂₄H₂₈N₂O₅
Molar mass	424.497 g·mol
3D model (JSmol)	Interactive image
SMILES O=C(OCC)(N2C(=O)N(c1ccccc1CC2)CC(=O)O)CCc3ccccc3
InChI InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1 Key:XPCFTKFZXHTYIP-PMACEKPBSA-N
(verify)

Benazepril, sold under the brand name Lotensin among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Versions are available as the combinations benazepril/hydrochlorothiazide and benazepril/amlodipine.

Common side effects include feeling tired, dizziness, cough, and light-headedness with standing. Serious side effects may include kidney problems, low blood pressure, high blood potassium, and angioedema. Use in pregnancy may harm the baby, while use when breastfeeding may be safe. It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity.

Benazepril was patented in 1981 and came into medical use in 1990. It is available as a generic medication. In 2022, it was the 159th most commonly prescribed medication in the United States, with more than 3 million prescriptions.

Medical uses

Lotensin is indicated for the treatment of hypertension, to lower blood pressure.

Side effects

The most common side effects patients experience are a headache or a chronic cough. The chronic cough develops in about 20% of people treated.

Contraindications

Benazepril can harm the fetus.

Dosage forms

It is also available in combination with hydrochlorothiazide, under the brand name Lotensin HCT, and with amlodipine (Lotrel).

Veterinary uses

Under the brand names Fortekor (Novartis) and VetACE (Jurox Animal Health), benazepril is used to treat congestive heart failure in dogs and chronic kidney failure in cats and dogs.

References

^ "Lotensin- benazepril hydrochloride tablet". DailyMed. 21 January 2019. Retrieved 11 February 2024.
^ "Benazepril Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
"Benazepril Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Benazepril Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
Dykewicz MS (April 2004). "Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into Mechanisms and Management". Medscape. Retrieved 2 April 2014.
"Lotensin package insert" (PDF). U.S. Food and Drug Administration (FDA). 2011. Retrieved 9 December 2020.
"Fortekor Flavor Tabs (5 mg) for Animal Use (Canada)". Drugs.com. Retrieved 3 June 2024.
"VetACE® - Jurox". www.jurox.com.au. Retrieved 3 June 2024.
King JN, Mauron C, Kaiser G (December 1995). "Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs". American Journal of Veterinary Research. 56 (12): 1620–1628. doi:10.2460/ajvr.1995.56.12.1620. PMID 8599524.
O'Grady MR, O'Sullivan ML, Minors SL, Horne R (2009). "Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers". Journal of Veterinary Internal Medicine. 23 (5): 977–983. doi:10.1111/j.1939-1676.2009.0346.x. PMID 19572914.
"Fortekor Flavor Tabs (5 mg) (Canada) for Animal Use". Drugs.com. Retrieved 9 December 2020.

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan Telmisartan (+amlodipine, +amlodipine and HCT, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

v t e Angiotensin receptor modulators
ATRTooltip Angiotensin receptor	Agonists: Angiotensin II Angiotensin III Angiotensin IV L-163,491 Saralasin Antagonists: Abitesartan Azilsartan Candesartan Elisartan Embusartan Eprosartan EXP-3174 Fimasartan Forasartan Irbesartan Losartan Milfasartan Olmesartan Olodanrigan PD123319 Pomisartan Pratosartan Ripisartan Saprisartan Sparsentan Tasosartan Telmisartan Valsartan Zolasartan ACE inhibitors: Alacepril Benazepril Captopril Cilazapril Delapril Enalapril Enalaprilat Fosinopril Gemopatrilat Imidapril Lisinopril Moexipril Omapatrilat Perindopril Quinapril Quinaprilat Ramipril Rentiapril Rescinnamine Spirapril Spiraprilat Temocapril Trandolapril Zofenopril Zofenoprilat Renin inhibitors: Aliskiren Ciprokiren Ditekiren Enalkiren Imarikiren Pepstatin Remikiren Terlakiren Zankiren Propeptides: Angiotensinogen Angiotensin I
Combinations:	Amlodipine/valsartan Olmesartan/amlodipine Olmesartan/amlodipine/hydrochlorothiazide Valsartan/hydrochlorothiazide Valsartan/hydrochlorothiazide/amlodipine

Angiotensin receptor modulators

ATRTooltip Angiotensin receptor

Propeptides: Angiotensinogen
Angiotensin I

Combinations:

Portal:

Medicine

Categories: